More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$668122914
EPS
-1.59
P/E ratio
--
Price to sales
46.85
Dividend yield
--
Beta
2.436328
Previous close
$11.37
Today's open
$11.28
Day's range
$10.73 - $11.32
52 week range
$10.73 - $35.34
show more
CEO
David Campbell
Employees
113
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
61183417
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript
Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President, Co-Founder, CEO & Director Conference Call Participants Chad Rubin Matthew Phipps - William Blair & Company L.L.C., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Jeffrey LaRosa - Leerink Partners LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to Janux Therapeutics Janux011 Phase I Healthy Volunteer Data and Autoimmune Development Strategy Call.
Seeking Alpha • Nov 9, 2026

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux's proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo.
Business Wire • Nov 9, 2026

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President a.
Business Wire • Nov 5, 2026

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET.David Campbell, Ph.D., President and Chief Executive Officer, will present initial clinical data from the Phase 1 single-ascending-dose study of JANX011 in healthy volunteers. The presentation will review safety, pharmacokinetics and pharmacodynamic.
Business Wire • Nov 2, 2026

4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Zacks Investment Research • Sep 15, 2026

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.
Business Wire • Sep 14, 2026

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
Zacks Investment Research • Aug 21, 2026

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. "During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment con.
Business Wire • Aug 6, 2026

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.
Zacks Investment Research • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Janux Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.